The FDA will select at most five companies that align with national priorities, including lower drug prices and increased ...

Biotech veteran and Stanford physician-scientist brings 30 years of translational research and regulatory experience to ...

The new pill, called AD109, is a combination of atomoxetine and aroxybutynin, two drugs that tell your brain to keep the ...

“They’ve realized that they can take a bit of a step further, that they can advance their policy priorities through those ...